^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Manufacturing and Marketing Approval Received in Japan for ALUNBRIG® in the Treatment of ALK Fusion Gene-positive Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer

Published date:
01/22/2021
Excerpt:
...Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that it has obtained approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market “ALUNBRIG® Tablets 30 mg, 90 mg" (brigatinib, development code: AP26113) as a first and second-line therapy for the treatment of patients with unresectable, advanced or recurrent ALK fusion gene-positive non-small cell lung cancer (ALK+ NSCLC).
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Excerpt:
...Typing of ALK fusion variants in tumor samples`Typing of ALK fusion variants in blood samples`Assessment of TP53 mutation status in tumor samples`Assessment of TP53 mutation status in blood samples`Detection of "acquired resistance" mutations via standardized next-generation sequencing (NGS)-based multiplex analysis in tumor samples`Detection of "acquired resistance" mutations via standardized next-generation sequencing (NGS)-based multiplex analysis in blood samples`Typing of ALK fusion variants in cerebrospinal fluid in "brain-only" progression.`...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Excerpt:
...Participants with unresectable advanced/recurrent ALK fusion gene-positive non-small cell lung cancer....
Trial ID:
More C2 evidence